|Location||Upcoming Cycle||Final Deadline||Start Date||End Date|
|Cairo||Cairo – Cycle 12||Feb 15, 2019||Jun 15, 2019|
|Jeddah||Jeddah – Cycle 9|
|Abu Dhabi||AD – Cycle 4|
|Beirut||Beirut – Cycle 4||Apr 15, 2019||May 15, 2019||Jun 15, 2019||Apply Now|
|Tunis||Tunis – Cycle 4||Mar 15, 2019||Apr 15, 2019||Jul 15, 2019||Apply Now|
|Bahrain||Bahrain – Cycle 3||Mar 31, 2019||Apr 15, 2019||Sep 15, 2019||Apply Now|
Dr. Hammach has over 20 years of leadership and management experience in R&D, venture capital investing, and strategy consulting for technology based organizations, including pharmaceuticals, biotech, medical device companies.
He is currently the Managing Director of RVC investment. Prior to this he was a senior advisor to the investment team at Riyadh Techno Valley (RTV) and a senior strategy consultant with Accenture, where he advised leading global organizations in the US and Europe on issues of growth strategy ranging from refinement of investment strategy and portfolio roadmap to corporate and commercial strategy.
Before joining Accenture, Dr. Hammach was a Venture Capital Investment Consultant with Aurora Funds, a leading Venture Capital firm in the North Carolina’s Research Triangle Park, USA. At Aurora Funds, he served with the Life Science and Healthcare Investment Team, assessing investment opportunities and managing portfolio companies.
Prior to this, Dr. Hammach was a Principal with Boehringer Ingelheim Pharmaceuticals (BIPI), in Ridgefield, Connecticut USA, the largest privately held pharmaceutical company in the world, where he held leadership roles within preclinical drug discovery in the area of inflammation. Under his leadership, his teams advanced several programs to preclinical development and filed for over 20 US patents.
Dr. Hammach served as a Postdoctoral fellow at the chemistry department of the University of Pennsylvania after having earned a Ph.D. in Chemistry from the University of Vermont. He also holds a MBA from Duke University, Fuqua School of Business, with concentration in Finance and Strategy. He is an inventor with over 17 US patents, covering novel anti-inflammatory drug candidates and has co-authored numerous articles in leading international journals and magazines.